Vetr Upgrade To 5-Stars Aid Horizon Pharma Recovery

Horizon Pharma Inc.

shares are trading higher by $0.77 at $14.20 in Wednesday's session. One day removed from its nearly $5 drubbing on Tuesday ($18.22 to $13.43), which was instigated by a disappointed sales guidance. That has not stooped the crowed-sourcing ratings agency Vetr to upgrade the issue to a 5-Stars. After a higher open it came down and found support ahead of Tuesday's low ($13.18), only reaching $13.26 before rallying into the $14 handle. So far, the current high stands at $14.28, which is quite some distance from Tuesday's high ($15.36). Above that level, the charts are wide open as no trading has occurred between Tuesday's high ($15.36) and Monday's low ($18.16).